Drugs & Targets FDA, Flatiron Health renew five-year research collaboration on real-world data September 15, 2023Vol.49 No.34
Drugs & Targets FDA grants accelerated approval to Elrexfio for r/r multiple myeloma September 08, 2023Vol.49 No.33
Drugs & Targets FDA places partial clinical hold for magrolimab studies in AML September 08, 2023Vol.49 No.33
Drugs & Targets FDA expands Reblozyl’s indication to first-line treatment of anemia in lower-risk myelodysplastic syndromes September 08, 2023Vol.49 No.33
Drugs & Targets FDA clears AION’s continuous temperature monitoring device and software platform September 08, 2023Vol.49 No.33
Drugs & Targets EC approves Keytruda + trastuzumab + chemo for first-line treatment of GEJ cancer September 08, 2023Vol.49 No.33
Drugs & Targets EMA validates odronextamab application for R/R follicular lymphoma and DLBCL September 08, 2023Vol.49 No.33
